Revolution Medicines, Inc.

NASDAQ (USD): Revolution Medicines, Inc. (RVMD)

Last Price

43.93

Today's Change

-0.13 (0.29%)

Day's Change

43.15 - 44.17

Trading Volume

729,998

Overview

Market Cap

8 Billion

Shares Outstanding

182 Million

Avg Volume

1,581,711

Avg Price (50 Days)

51.69

Avg Price (200 Days)

42.91

PE Ratio

-12.00

EPS

-3.66

Earnings Announcement

24-Feb-2025

Previous Close

44.06

Open

43.61

Day's Range

43.155 - 44.17

Year Range

25.93 - 62.4

Trading Volume

729,998

Price Change Highlight

1 Day Change

-0.30%

5 Day Change

-2.96%

1 Month Change

-22.59%

3 Month Change

3.05%

6 Month Change

14.97%

Ytd Change

55.61%

1 Year Change

52.01%

3 Year Change

59.46%

5 Year Change

52.01%

10 Year Change

52.01%

Max Change

52.01%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment